Co-Authors
This is a "connection" page, showing publications co-authored by Michael Chan and William Petty.
Connection Strength
0.515
-
Lanier CM, Hughes R, Ahmed T, LeCompte M, Masters AH, Petty WJ, Ruiz J, Triozzi P, Su J, O'Neill S, Watabe K, Cramer CK, Laxton AW, Tatter SB, Wang G, Whitlow C, Chan MD. Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. Neurooncol Pract. 2019 Sep; 6(5):402-409.
Score: 0.167
-
Shenker RF, McTyre ER, Ruiz J, Weaver KE, Cramer C, Alphonse-Sullivan NK, Farris M, Petty WJ, Bonomi MR, Watabe K, Laxton AW, Tatter SB, Warren GW, Chan MD. The Effects of smoking status and smoking history on patients with brain metastases from lung cancer. Cancer Med. 2017 May; 6(5):944-952.
Score: 0.148
-
Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, Ellis TL, McMullen KP, Shaw EG, Chan MD. Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Neurosurgery. 2013 Oct; 73(4):641-7; discussion 647.
Score: 0.116
-
Su J, Huang LS, Barnard R, Parks G, Cappellari J, Bellinger C, Dotson T, Craddock L, Prakash B, Hovda J, Clark H, Petty WJ, Pasche B, Chan MD, Miller LD, Ruiz J. Comprehensive and Computable Molecular Diagnostic Panel (C2Dx) From Small Volume Specimens for Precision Oncology: Molecular Subtyping of Non-Small Cell Lung Cancer From Fine Needle Aspirates. Front Oncol. 2021; 11:584896.
Score: 0.049
-
Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS One. 2016; 11(10):e0164244.
Score: 0.036